Tiny Health Raises $8.5M Series A Funding

Tiny Health has secured $8,500,000 in investment, bolstering its mission to advance at-home microbiome health.

The company operates a leading platform offering comprehensive gut and vaginal microbiome testing across various life stages, from pregnancy and infancy to adulthood and healthy aging.

This funding round marks a significant milestone as Tiny Health expands its capabilities in the preventative health sector.

The platform provides advanced testing, empowering individuals and practitioners to manage chronic conditions and optimize long-term health.

Using shotgun metagenomic sequencing and AI-driven analysis, Tiny Health delivers insights into early signs of inflammaging, chronic disease risk, and healthspan-related markers.

The company is trusted by over 80,000 families and individuals, and its tests are utilized by top clinicians and integrated with partners like Mayo Clinic’s Longevity & Executive Health Clinic, Superpower, and Mito Health.

This capital infusion is expected to accelerate Tiny Health’s operational expansion and research efforts.

The company plans to use the funds for growth initiatives, including enhancing its technology platform, scaling its reach, and further developing its scientific insights.

Tiny Health recently published a clinical study demonstrating an 83% reduction in the odds of developing atopic conditions with its testing, highlighting its commitment to evidence-based health solutions.

With a team comprising scientists and physicians from institutions such as Mayo Clinic, Johns Hopkins, and Stanford, Tiny Health is positioned to continue its trajectory in the personalized health industry.

The investment underscores confidence in the company’s approach to leveraging microbiome science for better health outcomes and its future growth plans in a rapidly evolving market.